The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II study of pemetrexed plus carboplatin followed by pemetrexed versus paclitaxel plus carboplatin followed by pemetrexed in advanced nonsquamous, non-small cell lung cancer (LOGIK 0904).
Koichi Takayama
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Pfizer
Research Funding - Chugai Pharma; Kyowa Hakko Kirin; Taiho Pharmaceutical
Koji Inoue
No relevant relationships to disclose
Masafumi Takeshita
No relevant relationships to disclose
Naoki Tashiro
No relevant relationships to disclose
Taishi Harada
No relevant relationships to disclose
Takashi Seto
Honoraria - Bristol-Myers Squibb; Lilly; Nippon Kayaku
Tomotoshi Imanaga
No relevant relationships to disclose
Noriko Fujimoto
No relevant relationships to disclose
Noriaki Nakagaki
No relevant relationships to disclose
Masayuki Kawasaki
No relevant relationships to disclose
Junji Kishimoto
No relevant relationships to disclose
Yukito Ichinose
Honoraria - Bristol-Myers Squibb; Lilly; Nippon Kayaku